New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:07 EDTISIS, GSKIsis Pharmaceuticals earns $3.0M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $3.0M milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs. GlaxoSmithKline and Isis have established an alliance focused on leveraging antisense technology to develop drugs to treat rare and infectious diseases. Current development-stage programs include ISIS-TTRRx for patients with familial transthyretin polyneuropathy, ISIS-HBVRx for patients with hepatitis B virus and ISIS-GSK4Rx for patients with an undisclosed ocular disorder.
News For ISIS;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:19 EDTGSKIBC Life Sciences to hold a conference
Subscribe for More Information
October 17, 2014
14:50 EDTGSKBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
11:17 EDTGSKGSK says Ebola vaccine too late for current epidemic, BBC reports
Subscribe for More Information
October 15, 2014
09:57 EDTISISLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
13:09 EDTGSKGlaxoSmithKline seeks binding bids for mature drugs, Reuters reports
Subscribe for More Information
11:23 EDTGSKBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTGSKNIH says several potential Ebola treatments under development
Subscribe for More Information
10:10 EDTGSKNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
October 13, 2014
07:12 EDTGSK, ISISOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 10, 2014
09:00 EDTISISOn The Fly: Pre-market Movers
Subscribe for More Information
05:22 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx Phase 2 study
Subscribe for More Information
October 9, 2014
07:02 EDTGSK, ISISIsis Pharmaceuticals receives $18M milestone payment from GlaxoSmithKline
Subscribe for More Information
October 8, 2014
11:10 EDTISISOptions with increasing implied volatility
Subscribe for More Information
06:11 EDTGSKNovartis says expects three executive committee members to leave
Novartis (NVS) confirmed that following completion of the transactions with GlaxoSmithKline (GSK) and Eli Lilly and Company (LLY) in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis. The expected changes to the ECN are subject to the closing of the transactions announced on April 22 - Novartis expects the transaction with GSK to be completed in the first half of 2015, and the transaction with Eli Lilly for its Animal Health Business to close in the first quarter of 2015. George Gunn, currently Division Head, Novartis Animal Health, will reach his contractual retirement age in July 2015 and will retire from Novartis. Upon closing of the Animal Health transaction with Lilly he will leave the ECN. Brian McNamara, currently Division Head, Novartis OTC, will transition to GSK as Head of Americas and Europe for the consumer health businesses, reporting to the President of GSK Consumer Healthcare, effective at closing of the transaction. Andrin Oswald, currently Division Head, Novartis Vaccines, will be leaving Novartis to pursue other opportunities following closing of the transaction with GSK.
October 7, 2014
10:56 EDTISISOptions with increasing implied volatility
Subscribe for More Information
October 6, 2014
14:24 EDTISISIsis Pharmaceuticals volatility elevated into update on Phase 2 clinical studies
Isis Pharmaceuticals October weekly call option implied volatility is at 120, October is at 94, November is at 73, January is at 64; compared to its 26-week average of 65 according to Track Data, suggesting large price movement into management providing an update on the Phase 2 clinical studies of ISIS-SMN Rx results presented at the 19th International World Muscle Society Congress on October 10.
07:13 EDTISISMobile Marketing & Technology Magazine to hold a conference
Mobile Payments Conference is being held in Chicago on October 6-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use